EUVIMEDEUVIMED entdecken
Validierungsstudie

Validation of a Lenvatinib Assay: A Pilot Study

Monica Majumder iD, Lucy E Ding, Cameron Wood, Christopher Hodgkins, Eleanor White, Bruce G Robinson, Roderick J Clifton-Bligh, Paul Bonnitcha, Matti L Gild

Endocrine Research · 2025

DOI: 10.1080/07435800.2025.2509986 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Endocrine Research, 2025. Verfasst von Monica Majumder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Thyroid Neoplasms, Antineoplastic Agents. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Lenvatinib has demonstrated efficacy in improving progression-free and overall survival in patients with radioiodine refractory thyroid cancer. However, treatment-related adverse events (TRAEs) frequently cause dose interruptions and suboptimal dosing, underscoring the importance of monitoring of lenvatinib levels. Currently, there is no validated lenvatinib assay for clinical use. We describe the development of a mass spectrometry assay for accurate quantification of lenvatinib, along with a pilot study reporting peak and trough levels. DESIGN, PATIENTS AND MEASUREMENTS: A pilot prospective single-center study was conducted at Royal North Shore Hospital, to develop and validate an in-house high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for measuring plasma lenvatinib levels in patients with radioiodine refractory thyroid cancer. Patient data including dosage, TRAEs, and disease progression were recorded. RESULTS: Lenvatinib doses ranged between 4 mg to 14 mg daily. Trough and peak levels were measured in nine and eight patients respectively. Duration of treatment ranged from 7 to 63 months (mean 29 months), with treatment duration at the time of testing ranging from 1 to 14 months. Trough levels ranged from 4.60 to 30.53 µg/L (median 21.74 µg/L). Peak levels for patients receiving 10 mg (n = 3) ranged from 78.50 to 237.72 µg/L (median 129.56 µg/L), while those receiving 14 mg (n = 4) ranged from 65.10 to 263.64 µg/L (median 185.23 µg/L). CONCLUSIONS: Our study describes the successful development of a novel LC-MS/MS assay for quantifying plasma lenvatinib levels. Despite consistent dosing, we observed considerable variability in levels in this group. Further research is required to examine the utility of lenvatinib drug monitoring in the setting of thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesThyroid NeoplasmsAntineoplastic AgentsDrug MonitoringHumansPilot ProjectsMaleFemaleMiddle AgedAgedTandem Mass SpectrometryAdultProspective StudiesChromatography, High Pressure LiquidProtein Kinase Inhibitors

Stichwörter der Autor:innen

Chromatographylenvatinibliquidprotein kinase inhibitorsthyroid neoplasms

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, NSW, Australia.
  • NSW Health Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Cancer Genetics Laboratory, Kolling Institute of Medical Research, Sydney, NSW, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

ORCID-Profile: Monica Majumder

Zitieren

APA

Majumder, M., Ding, L. E., Wood, C., Hodgkins, C., White, E., Robinson, B. G., Clifton-Bligh, R. J., Bonnitcha, P., & Gild, M. L. (2025). Validation of a Lenvatinib Assay: A Pilot Study. Endocrine Research. https://doi.org/10.1080/07435800.2025.2509986

Vancouver

Majumder M, Ding LE, Wood C, Hodgkins C, White E, Robinson BG, et al. Validation of a Lenvatinib Assay: A Pilot Study. Endocrine Research. 2025. doi:10.1080/07435800.2025.2509986

BibTeX
@article{Majumder2025,
  author = {Majumder, Monica and Ding, Lucy E and Wood, Cameron and Hodgkins, Christopher and White, Eleanor and Robinson, Bruce G and Clifton-Bligh, Roderick J and Bonnitcha, Paul and Gild, Matti L},
  title = {Validation of a Lenvatinib Assay: A Pilot Study},
  journal = {Endocrine Research},
  year = {2025},
  doi = {10.1080/07435800.2025.2509986}
}
Kostenlos starten →